Izalontamab SI-B001 is a significant advance in the management of difficult-to-treat multiple myeloma. This innovative antibody directly binds to BCMA on myeloma malignancies, leading to BCMA-dependent cellular https://recombinantizalontamab574880.blog5.net/95997739/izalontamab-si-b001-a-promising-emerging-antibody-treatment